Artios Pharma Ltd., the Cambridge, UK-based biotech focusing on the DNA damage response (DDR) to develop first-in-class cancer treatments, has raised £65 million ($83 million) in a series B round led by Andera Partners (formerly EdRIP) and LSP (Life Science Partners) alongside new investors Novartis Venture Fund and Pfizer Ventures and existing shareholders Arix Bioscience, SV Health Investors, M Ventures, IP Group and Abbvie Ventures.
Acknowledging that the fundraising was executed earlier than had originally been anticipated, Artios CEO Niall Martin revealed to Scrip that...






